68Ga-NOTA-Aca-BBN(7-14) PET/CT in healthy volunteers and glioma patients

Journal of Nuclear Medicine

Volumn 57, Issue 1, 2016, Pages 9-14

  Zhang, Jingjing ^a,b   Li, Deling ^c   Lang, Lixin ^b   Zhu, Zhaohui ^a   Wang, Ling ^a   Wu, Peilin ^a   Niu, Gang ^b   Li, Fang ^a   Chen, Xiaoyuan ^b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

68Ga BBN; BBN peptide; Gastrin releasing peptide receptor (GRPR); Glioma; PET CT

Indexed keywords

AMINO ACID; BOMBESIN; GALLIUM 68; GASTRIN RELEASING PEPTIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; 1,4,7-TRIAZACYCLONONANE-N,N',N''-TRIACETIC ACID; BOMBESIN (7-14); BOMBESIN RECEPTOR; GALLIUM; HETEROCYCLIC COMPOUND; PEPTIDE FRAGMENT;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ARTICLE; ASTROCYTOMA; BRAIN THIRD VENTRICLE; CANCER GRADING; CEREBELLUM; CHILD; CIRCULATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DOSIMETRY; DRUG TOLERABILITY; FEMALE; FRONTAL LOBE; GLIA CELL; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY; LABORATORY TEST; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PILOCYTIC ASTROCYTOMA; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; TEMPORAL LOBE; THALAMUS; URINARY TRACT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL; GENE EXPRESSION REGULATION; METABOLISM; NORMAL HUMAN; PROCEDURES; RADIOGRAPHY; SAFETY; SCINTISCANNING; TISSUE DISTRIBUTION; YOUNG ADULT;

ADOLESCENT; ADULT; BOMBESIN; CHILD; CHILD, PRESCHOOL; FEMALE; GALLIUM RADIOISOTOPES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HEALTHY VOLUNTEERS; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, BOMBESIN; SAFETY; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84958646629     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.115.165316     Document Type: Article

References (48)

1. Ananias HJ, van den Heuvel MC, Helfrich W, de Jong IJ. Expression of the gastrin?releasing peptide receptor, the prostate stem cell antigen and the prostatespecific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate. 2009;69:1101-1108.
2. Yang M, Gao H, Zhou Y, et al. 18F-labeled GRPR agonists and antagonists: a comparative study in prostate cancer imaging. Theranostics. 2011;1:220-229.
3. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152-1159.
4. Reubi JC, Körner M, Waser B, Mazzucchelli L, Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging. 2004;31:803-810.
5. Heuser M, Schlott T, Schally A, et al. Expression of gastrin releasing peptide receptor in renal cell carcinomas: a potential function for the regulation of neoangiogenesis and microvascular perfusion. J Urol. 2005;173:2154-2159.
6. Fleischmann A, Waser B, Reubi JC. Overexpression of gastrin-releasing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms. Cell Oncol. 2007;29:421-433.
7. Brat DJ, Prayson RA, Ryken TC, Olson JJ. Diagnosis of malignant glioma: role of neuropathology. J Neurooncol. 2008;89:287-311.
8. Farias CB, Lima RC, Lima LO, et al. Stimulation of proliferation of U138-MG glioblastoma cells by gastrin-releasing peptide in combination with agents that enhance cAMP signaling. Oncology. 2008;75:27-31.
9. Sharif TR, Luo W, Sharif M. Functional expression of bombesin receptor in most adult and pediatric human glioblastoma cell lines: role in mitogenesis and in stimulating the mitogen-activated protein kinase pathway. Mol Cell Endocrinol. 1997;130:119-130.
10. Flores DG, Meurer L, Uberti AF, et al. Gastrin-releasing peptide receptor content in human glioma and normal brain. Brain Res Bull. 2010;82:95-98.
11. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo. Cancer Res. 1994;54:5895-5901.
12. Kiaris H, Schally AV, Sun B, Armatis P, Groot K. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide. Oncogene. 1999;18:7168-7173.
13. de Oliveira MS, Cechim G, Braganhol E, et al. Anti-proliferative effect of the gastrin-release peptide receptor antagonist RC-3095 plus temozolomide in experimental glioblastoma models. J Neurooncol. 2009;93:191-201.
14. Carlucci G, Kuipers A, Ananias H, et al. GRPR-selective PET imaging of prostate cancer using [18F]-lanthionine-bombesin analogs. Peptides. 2015;67:45-54.
15. Chen X, Park R, Hou Y, et al. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med. 2004;45:1390-1397.
16. Garrison JC, Rold TL, Sieckman GL, et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: sideby-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med. 2007;48:1327-1337.
17. Reubi JC, Mäcke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med. 2005;46(suppl):67S-75S.
18. Zhang X, Cai W, Cao F, et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med. 2006;47:492-501.
19. Smith CJ, Volkert WA, Hoffman TJ. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol. 2005;32: 733-740.
20. Prasanphanich AF, Nanda PK, Rold TL, et al. [64Cu-NOTA-8-Aoc-BBN(7-14) NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci USA. 2007;104: 12462-12467.
21. Mansi R, Wang X, Forrer F, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging. 2011;38:97-107.
22. Pourghiasian M, Liu Z, Pan J, et al. 18F-AmBF 3-MJ9: a novel radiofluorinated bombesin derivative for prostate cancer imaging. Bioorg Med Chem. 2015;23: 1500-1506.
23. Kunstler J-U, Veerendra B, Figueroa SD, et al. Organometallic 99mTc(III) '41 1' bombesin (7-14) conjugates: synthesis, radiolabeling, and in vitro/in vivo studies. Bioconjug Chem. 2007;18:1651-1661.
24. Chatalic KL, Franssen GM, Van Weerden WM, et al. Preclinical comparison of Al18F-and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer. J Nucl Med. 2014;55:2050-2056.
25. Van de Wiele C, Dumont F, Dierckx RA, et al. Biodistribution and dosimetry of 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med. 2001;42:1722-1727.
26. Van de Wiele C, Phonteyne P, Pauwels P, et al. Gastrin-releasing peptide receptor imaging in human breast carcinoma versus immunohistochemistry. J Nucl Med. 2008;49:260-264.
27. Nock B, Maina T. Tetraamine-coupled peptides and resulting 99mTc-radioligands: an effective route for receptor-targeted diagnostic imaging of human tumors. Curr Top Med Chem. 2012;12:2655-2667.
28. Ananias HJ, Yu Z, Dierckx RA, et al. 99mtechnetium-HYNIC (tricine/TPPTS)-Aca-bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model. Mol Pharm. 2011;8:1165-1173.
29. Ananias HJ, Yu Z, Hoving HD, et al. Application of 99m technetium-HYNIC (tricine/TPPTS)-aca-bombesin (7-14) SPECT/CT in prostate cancer patients: a first-in-man study. Nucl Med Biol. 2013;40:933-938.
30. Van de Wiele C, Dumont F, Broecke RV, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med. 2000;27:1694-1699.
31. Scopinaro F, Varvarigou A, Ussof W, et al. Technetium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. Cancer Biother Radiopharm. 2002;17:327-335.
32. Scopinaro F, Varvarigou A, Ussof W, et al. Breast cancer takes up 99mTc bombesin: a preliminary report. Tumori. 2002;88(suppl):S25-S28.
33. Galldiks N, Langen KJ, Pope WB. From the clinician's point of view: what is the status quo of positron emission tomography in patients with brain tumors? Neuro-Oncol. June 30, 2015 [Epub ahead of print].
34. Liu Z, Niu G, Wang F, Chen X. 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging. 2009;36:1483-1494.
35. Louis DN, Ohgaki H,Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl). 2007;114:97-109.
36. Louis DN, Perry A, Burger P, et al. International Society of Neuropathology? Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014;24:429-435.
37. Lassmann M, Chiesa C, Flux G, Bardies M. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38:192-200.
38. Zhang J, Lang L, Zhu Z, Li F, Niu G, Chen X. Clinical translation of an albuminbinding PET radiotracer 68Ga-NEB. J Nucl Med. 2015;56:1609-1614.
39. Roivainen A, Kähkönen E, Luoto P, et al. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013;54:867-872.
40. Wang Z, Zhang M, Wang L, et al. Prospective study of 68Ga-NOTA-NFB: radiation dosimetry in healthy volunteers and first application in glioma patients. Theranostics. 2015;5:882-889.
41. Gonzalez N, Moody TW, Igarashi H, Ito T, Jensen RT. Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states. Curr Opin Endocrinol Diabetes Obes. 2008;15:58-64.
42. Breeman WA, Verbruggen AM. The 68Ge/68Ga generator has high potential, but when can we use 68Ga-labelled tracers in clinical routine? Eur J Nucl Med Mol Imaging. 2007;34:978-981.
43. Mittra ES, Goris ML, Iagaru AH, et al. Pilot pharmacokinetic and dosimetric studies of 18F-FPPRGD2: a PET radiopharmaceutical agent for imaging avb3 integrin levels. Radiology. 2011;260:182-191.
44. Rogers BE, Bigott HM, McCarthy DW, et al. MicroPET imaging of a gastrinreleasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem. 2003;14:756-763.
45. Parry JJ, Kelly TS, Andrews R, Rogers BE. In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties. Bioconjug Chem. 2007;18:1110-1117.
46. Strauss LG, Koczan D, Seiz M, et al. Correlation of the Ga-68-bombesin analog Ga-68-BZH3 with receptors expression in gliomas as measured by quantitative dynamic positron emission tomography (dPET) and gene arrays. Mol Imaging Biol. 2012;14:376-383.
47. Price SJ, Gillard JH. Imaging biomarkers of brain tumour margin and tumour invasion. Br J Radiol. 2011;84(suppl):S159-S167.
48. Roberts DW, Valdés PA, Harris BT, et al. Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between d-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. J Neurosurg. 2011;114:595-603.